A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
Although the study did not meet the predefined endpoint for PFS improvement, promising signals of efficacy warrant future investigation including response/resistance biomarkers to inform patient selection.
Authors
- Breelyn A. Wilky (ORCID: https://orcid.org/0000-0001-5080-497X)
- Sofia Chaudhry
- Qierra R. Brockman (ORCID: https://orcid.org/0000-0001-8562-4565)
- Nicholas R. Therrien (ORCID: https://orcid.org/0000-0001-5202-853X)
- Alessandra Maleddu (ORCID: https://orcid.org/0000-0001-9063-7862)
- Katherine Julian (ORCID: https://orcid.org/0000-0003-3427-9997)
- Dexiang Gao (ORCID: https://orcid.org/0000-0003-3920-7060)
- Jeffrey D. Rytlewski (ORCID: https://orcid.org/0000-0003-0010-7548)
- Eduardo Dávila (ORCID: https://orcid.org/0000-0001-9738-4167)
- Cristiam Moreno Tellez (ORCID: https://orcid.org/0000-0001-8064-0865)
- Anthony Elias (ORCID: https://orcid.org/0000-0002-6509-9211)
- Anne C. Mailhot
- Chelsey R. Cartwright
- Lindsey E. Kemp
Institutions
- University of Colorado Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0618
- Citations
- 3
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Cancer League of Colorado
- Cancer Center, University of Colorado
- National Cancer Institute